DOI: 10.1192/j.eurpsy.2026.10931 ISSN: 0924-9338

Intranasal Air Suction Approach for Management of Acute Migraine Headache: An International Perspective

J. Jeyapalan, M. Nissila, S. Sihvonen

Introduction

Migraine is a disabling neurological disorder affecting over one billion people worldwide. Despite advances in treatment, the precise mechanisms remain unclear. The Sinus Hypoxic Nitric Oxide Theory (SHNOT) suggests that excessive sinus nitric oxide (sNO), generated under hypoxic conditions, plays a central role in migraine pathophysiology.

Objectives

This study aimed to evaluate and compare two nasal-based interventions—intranasal drug administration (INDAA) and paranasal air suction approach (PNASA)—for acute migraine management. Specific objectives were to:

1)

Assess their efficacy in rapid symptom relief,

2)

Compare safety and side-effect profiles,

3)

Examine the mechanistic role of sNO and sCO,

4)

Validate SHNOT as a theoretical framework.

Methods

An integrative review was conducted. Literature searches in PubMed, Google Scholar, and Cochrane identified 312 records. After screening, 11 studies met the inclusion criteria. Thematic analysis was applied across randomised trials, case series, meta-analyses, and gas analysis studies.

Results

INDAA agents (zolmitriptan, lidocaine, hydroxocobalamin, oxymetazoline) showed variable efficacy, often accompanied by local irritation or systemic effects. In contrast, PNASA studies consistently demonstrated rapid migraine relief within 1–2 minutes, with no adverse effects reported (Figure 1).

Table 1.

summarises key outcomes

Table 1. Long description.

Intervention
N (participants)
Onset of Relief Adverse Effects
Zolmitriptan (5 mg nasal spray)
798
≤2 h Mild systemic effects
Intranasal Lidocaine
134 (meta-analysis) ≤5 min Local irritation (~49%)
Hydroxocobalamin (1 mg intranasal)
20 Prophylactic (3 mo) Well tolerated
Oxymetazoline (0.1%)
108 ≤15 min Potential rebound congestion
PNASA (air suction)
184 1–2 min None observed
Image 1:

Conclusions

Paranasal air suction represents a safe, non-invasive, and cost-effective acute migraine treatment. Findings strongly support SHNOT, positioning sNO as a key causative molecule. PNASA shows superior efficacy and tolerability compared to INDAA, highlighting its potential as a first-line intervention in diverse healthcare settings.

Disclosure of Interest

None Declared

More from our Archive